DCM
ACAD icon

Dupont Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Dupont Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,228
Closed -$211K – 749
2022
Q4 		$211K Sell
13,228
-27,166
-67% -$425K 0.01% 777
2022
Q3 		$661K Buy
40,394
+20,011
+98% +$324K 0.04% 541
2022
Q2 		$287K Hold
20,383
– – 0.01% 871
2022
Q1 		$494K Sell
20,383
-1,803
-8% -$43.6K 0.02% 752
2021
Q4 		$518K Buy
22,186
+6,671
+43% +$134K 0.02% 760
2021
Q3 		$258K Buy
+15,515
New +$299K 0.01% 1124
2021
Q2 		– Sell
-3,188
Closed -$82K – 1717
2021
Q1 		$82K Sell
3,188
-7,181
-69% -$316K ﹤0.01% 1379
2020
Q4 		$554K Buy
10,369
+2,853
+38% +$142K 0.01% 802
2020
Q3 		$310K Buy
7,516
+4,454
+145% +$192K 0.01% 958
2020
Q2 		$148K Sell
3,062
-16,040
-84% -$770K ﹤0.01% 1196
2020
Q1 		$807K Sell
19,102
-2,404
-11% -$99.1K 0.02% 515
2019
Q4 		$920K Buy
21,506
+3,685
+21% +$160K 0.02% 600
2019
Q3 		$641K Sell
17,821
-1,911
-10% -$57.9K 0.01% 674
2019
Q2 		$527K Buy
+19,732
New +$504K 0.01% 757

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dupont Capital Management's ACAD Position: Q1 2023 in Review

Dupont Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 13,228 shares — an estimated $211K sold.

Dupont Capital Management first reported a position in ACAD in Q2 2019 and held it in 14 quarters. The position peaked at $920K in Q4 2019. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Dupont Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 13,228 Acadia Pharmaceuticals shares in Q1 2023, an estimated $211K.
  • Dupont Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 14 quarters.
  • Dupont Capital Management's Acadia Pharmaceuticals position peaked at $920K in Q4 2019.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.